Inhibitor Therapeutics Debt to Equity

The latest debt-to-equity ratio for CBTE is -1.19. That is above the Healthcare sector average of -8.5. Investors often review this figure alongside Inhibitor Therapeutics's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, CBTE currently prints -1.19 for debt-to-equity ratio, while the sector average sits near -8.5. That is roughly 86.0% above the sector mean. Large gaps often invite a closer look at Inhibitor Therapeutics's growth, margins, and balance sheet.

A debt-to-equity ratio of -1.19 for Inhibitor Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (-8.5) and with CBTE's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting CBTE's debt-to-equity ratio (-1.19), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Inhibitor Therapeutics's debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.